Posted by Michael Wonder on 18 Feb 2025
Nemolizumab approved to treat prurigo nodularis and atopic dermatitis for patients in the UK
17 February 2025 - This national approval was granted after an Access Consortium new active substance work-sharing initiative (NASWSI) procedure.
The MHRA has today approved the medicine nemolizumab (Nemluvio) for the treatment of two skins conditions – moderate to severe prurigo nodularis for adults aged 18 and above, and moderate-to-severe atopic dermatitis (eczema) for adults and adolescents aged 12 and above.
